Genotypic resistance in HIV-Infected naive patients receiving abacavir plus lamivudine and efavirenz

被引：1
|
作者：
Ferrer, Elena [1 ]
Niubo, Jordi
Crespo, Manuel
Gatell, Josep Maria
Sanz, Jose
Veloso, Sergio
Llibre, Josep Maria
Barrufet, Pilar
Sanchez, Pochita
Podzamczer, Daniel
机构：
[1] Hosp Univ Bellvitge, Barcelona, Spain
[2] Hosp Gen Valle Hebron, Barcelona, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Hosp Principe Asturias, Alcala De Henares, Spain
[5] Hosp Joan 23, Tarragona, Spain
[6] Hosp Calella, Barcelona, Spain
[7] Hosp Mataro, Barcelona, Spain
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2007年 / 46卷 / 02期
关键词：
D O I：
10.1097/QAI.0b013e318074efd1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：253 / 255
页数：3
相关论文
共 50 条
  • [31] Abacavir plus dolutegravir plus lamivudine for the treatment of HIV
    Comi, Laura
    Maggiolo, Franco
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (15) : 2097 - 2106
  • [32] Effectiveness and safety of abacavir, lamivudine, and zidovudine in Antiretroviral therapy-naive HIV-infected patients -: Results from a large multicenter observational cohort
    Berenguer, J
    Pérez-Elías, MJ
    Bellón, JM
    Knobel, H
    Rivas-González, P
    Gatell, JM
    Miguélez, M
    Hernández-Quero, J
    Flores, J
    Soriano, V
    Santos, I
    Podzamczer, D
    Sala, M
    Camba, M
    Resino, S
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (02) : 154 - 159
  • [33] Efavirenz dose reduction in HIV-infected patients
    Vento, S.
    Lanzafame, M.
    Lattuada, E.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2013, 18 : 80 - 81
  • [34] Abacavir plus efavirenz plus background combination therapy as a salvage regimen in HIV-infected individuals:: efficacy and safety after 48 weeks
    Herhaus, C
    Wasmuth, JC
    Römer, K
    Salzberger, B
    Schliefer, K
    Rockstroh, JK
    AIDS, 2000, 14 : S39 - S39
  • [35] Efavirenz dose reduction in HIV-infected patients
    Lanzafame, M.
    Bonora, S.
    Lattuada, E.
    Vento, S.
    HIV MEDICINE, 2012, 13 (04) : 252 - 253
  • [36] Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment
    Rozenbaum, W
    Katlama, C
    Massip, P
    Bentata, M
    Zucman, D
    Delfraissy, JF
    Trepo, C
    David, F
    Lanier, ER
    Vavro, C
    Mamet, JP
    ANTIVIRAL THERAPY, 2001, 6 (02) : 135 - 142
  • [37] Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naive HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012
    Galindo, Jaime
    Amariles, Pedro
    Mueses-Marin, Hector F.
    Hincapie, Jaime A.
    Gonzalez-Avendano, Sebastian
    Galindo-Orrego, Ximena
    BMC INFECTIOUS DISEASES, 2016, 16
  • [38] Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz
    Re, MC
    Monari, P
    Bon, I
    Borderi, M
    Gibellini, D
    Schiavone, P
    Vitone, F
    Furlini, G
    La Placa, M
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (03) : 223 - 226
  • [39] Effectiveness and safety of an abacavir/lamivudine plus rilpivirine regimen for the treatment of HIV-1 infection in naive patients
    Curran, Adrian
    Rojas, Jhon
    Cabello, Alfonso
    Troya, Jesus
    Imaz, Arkaitz
    Domingo, Pere
    Martinez, Esteban
    Ryan, Pablo
    Gorgolas, Miguel
    Podzamczer, Daniel
    Knobel, Hernando
    Gutierrez, Felix
    Ribera, Esteban
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (12) : 3510 - 3514
  • [40] COST EFFECTIVENESS ANALYSIS OF THE COMBINATION TENOFOVIR (TDF)/EMTRICITABINA (FTC) plus EFAVIRENZ (EFV) IN HIV-INFECTED NAIVE PATIENTS IN MEXICO
    Soto Molina, H.
    Pizarro, M.
    Vargas, G.
    Rizzoli, A.
    VALUE IN HEALTH, 2012, 15 (04) : A245 - A245
12345